Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses LNA Technology to Idexx Labs for Veterinary Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has issued a non-exclusive license to Idexx Laboratories for its LNA (locked nucleic acid) technology for veterinary disease diagnostic products.

The deal provides Exiqon with upfront and milestone payments, as well as royalty payments on global sales of products covered by the agreement. Further financial details were not disclosed.

"We are excited that the LNA technology is now being applied in veterinary diagnostic products, which emphasizes the broad applicability of the LNA technology," Lars Kongsbak, president and CEO of Exiqon, said in a statement.

The deal is part of a strategy begun a year ago by the company to license out the technology in markets that Exiqon does not plan to pursue itself.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.